Cargando…

MIG (CXCL9), IP-10 (CXCL10) and I-TAC (CXCL11) concentrations after nasal allergen challenge in patients with allergic rhinitis

INTRODUCTION: The role of monokine induced by interferon-γ (IFN-γ, MIG/CXCL9), IFN-γ-inducible protein (IP-10/CXCL10), and IFN-inducible T cell α chemoattractant (I-TAC/CXCL11) in allergic inflammation has not been explored in detail in vivo. The aim of the study was to examine the changes in concen...

Descripción completa

Detalles Bibliográficos
Autores principales: Tworek, Damian, Kuna, Piotr, Młynarski, Wojciech, Górski, Paweł, Pietras, Tadeusz, Antczak, Adam
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Termedia Publishing House 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3832822/
https://www.ncbi.nlm.nih.gov/pubmed/24273568
http://dx.doi.org/10.5114/aoms.2013.37198
_version_ 1782291743833587712
author Tworek, Damian
Kuna, Piotr
Młynarski, Wojciech
Górski, Paweł
Pietras, Tadeusz
Antczak, Adam
author_facet Tworek, Damian
Kuna, Piotr
Młynarski, Wojciech
Górski, Paweł
Pietras, Tadeusz
Antczak, Adam
author_sort Tworek, Damian
collection PubMed
description INTRODUCTION: The role of monokine induced by interferon-γ (IFN-γ, MIG/CXCL9), IFN-γ-inducible protein (IP-10/CXCL10), and IFN-inducible T cell α chemoattractant (I-TAC/CXCL11) in allergic inflammation has not been explored in detail in vivo. The aim of the study was to examine the changes in concentrations of MIG/CXCL9, IP-10/CXCL10 and I-TAC/CXCL11 in nasal lavages collected from healthy and allergic subjects during nasal allergen challenge. MATERIAL AND METHODS: Subjects allergic to grass pollen and healthy controls were included. Nasal allergen challenge preceded by placebo administration was performed outside the pollen season. Nasal lavages were collected before and 30 min after application of the placebo and 30 min after allergen administration. Concentrations of chemokines were determined using ELISA. RESULTS: We observed significantly higher concentrations of IP-10/CXCL10 in allergic patients compared to the healthy subjects before (354.49 ±329.24 vs. 164.62 ±175.94 pg/ml; p = 0.036), 30 min after placebo (420.3 ±421.28 vs. 246.88 ±353.24 pg/ml; p = 0.021) and 30 min after allergen administration (403.28 ±359.29 vs. 162.68 ±148.69 pg/ml; p = 0.025). IP-10/CXCL10 levels did not change 30 min after allergen provocation. In contrast, MIG/CXCL9 levels were similar in both groups before and after placebo. However, a significant rise in MIG/CXCL9 concentration was noted in allergic patients 30 min after the allergen (138.88 ±109.59 vs. 395.8 ±301.2 pg/ml; p = 0.00026). I-TAC/CXCL11 concentrations increased after placebo as well as the allergen in both groups. CONCLUSIONS: IP-10/CXCL10 concentrations are elevated in nasal lavages from allergic patients and this chemokine may play a role in chronic allergic inflammation. MIG/CXCL9 levels increase rapidly after allergen application, which may suggest its role in the early allergic response. Results on I-TAC/CXCL11 concentrations remain inconclusive.
format Online
Article
Text
id pubmed-3832822
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Termedia Publishing House
record_format MEDLINE/PubMed
spelling pubmed-38328222013-11-22 MIG (CXCL9), IP-10 (CXCL10) and I-TAC (CXCL11) concentrations after nasal allergen challenge in patients with allergic rhinitis Tworek, Damian Kuna, Piotr Młynarski, Wojciech Górski, Paweł Pietras, Tadeusz Antczak, Adam Arch Med Sci Clinical Research INTRODUCTION: The role of monokine induced by interferon-γ (IFN-γ, MIG/CXCL9), IFN-γ-inducible protein (IP-10/CXCL10), and IFN-inducible T cell α chemoattractant (I-TAC/CXCL11) in allergic inflammation has not been explored in detail in vivo. The aim of the study was to examine the changes in concentrations of MIG/CXCL9, IP-10/CXCL10 and I-TAC/CXCL11 in nasal lavages collected from healthy and allergic subjects during nasal allergen challenge. MATERIAL AND METHODS: Subjects allergic to grass pollen and healthy controls were included. Nasal allergen challenge preceded by placebo administration was performed outside the pollen season. Nasal lavages were collected before and 30 min after application of the placebo and 30 min after allergen administration. Concentrations of chemokines were determined using ELISA. RESULTS: We observed significantly higher concentrations of IP-10/CXCL10 in allergic patients compared to the healthy subjects before (354.49 ±329.24 vs. 164.62 ±175.94 pg/ml; p = 0.036), 30 min after placebo (420.3 ±421.28 vs. 246.88 ±353.24 pg/ml; p = 0.021) and 30 min after allergen administration (403.28 ±359.29 vs. 162.68 ±148.69 pg/ml; p = 0.025). IP-10/CXCL10 levels did not change 30 min after allergen provocation. In contrast, MIG/CXCL9 levels were similar in both groups before and after placebo. However, a significant rise in MIG/CXCL9 concentration was noted in allergic patients 30 min after the allergen (138.88 ±109.59 vs. 395.8 ±301.2 pg/ml; p = 0.00026). I-TAC/CXCL11 concentrations increased after placebo as well as the allergen in both groups. CONCLUSIONS: IP-10/CXCL10 concentrations are elevated in nasal lavages from allergic patients and this chemokine may play a role in chronic allergic inflammation. MIG/CXCL9 levels increase rapidly after allergen application, which may suggest its role in the early allergic response. Results on I-TAC/CXCL11 concentrations remain inconclusive. Termedia Publishing House 2013-08-26 2013-10-31 /pmc/articles/PMC3832822/ /pubmed/24273568 http://dx.doi.org/10.5114/aoms.2013.37198 Text en Copyright © 2013 Termedia & Banach http://creativecommons.org/licenses/by-nc-nd/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-Noncommercial 3.0 Unported License, permitting all non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Clinical Research
Tworek, Damian
Kuna, Piotr
Młynarski, Wojciech
Górski, Paweł
Pietras, Tadeusz
Antczak, Adam
MIG (CXCL9), IP-10 (CXCL10) and I-TAC (CXCL11) concentrations after nasal allergen challenge in patients with allergic rhinitis
title MIG (CXCL9), IP-10 (CXCL10) and I-TAC (CXCL11) concentrations after nasal allergen challenge in patients with allergic rhinitis
title_full MIG (CXCL9), IP-10 (CXCL10) and I-TAC (CXCL11) concentrations after nasal allergen challenge in patients with allergic rhinitis
title_fullStr MIG (CXCL9), IP-10 (CXCL10) and I-TAC (CXCL11) concentrations after nasal allergen challenge in patients with allergic rhinitis
title_full_unstemmed MIG (CXCL9), IP-10 (CXCL10) and I-TAC (CXCL11) concentrations after nasal allergen challenge in patients with allergic rhinitis
title_short MIG (CXCL9), IP-10 (CXCL10) and I-TAC (CXCL11) concentrations after nasal allergen challenge in patients with allergic rhinitis
title_sort mig (cxcl9), ip-10 (cxcl10) and i-tac (cxcl11) concentrations after nasal allergen challenge in patients with allergic rhinitis
topic Clinical Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3832822/
https://www.ncbi.nlm.nih.gov/pubmed/24273568
http://dx.doi.org/10.5114/aoms.2013.37198
work_keys_str_mv AT tworekdamian migcxcl9ip10cxcl10anditaccxcl11concentrationsafternasalallergenchallengeinpatientswithallergicrhinitis
AT kunapiotr migcxcl9ip10cxcl10anditaccxcl11concentrationsafternasalallergenchallengeinpatientswithallergicrhinitis
AT młynarskiwojciech migcxcl9ip10cxcl10anditaccxcl11concentrationsafternasalallergenchallengeinpatientswithallergicrhinitis
AT gorskipaweł migcxcl9ip10cxcl10anditaccxcl11concentrationsafternasalallergenchallengeinpatientswithallergicrhinitis
AT pietrastadeusz migcxcl9ip10cxcl10anditaccxcl11concentrationsafternasalallergenchallengeinpatientswithallergicrhinitis
AT antczakadam migcxcl9ip10cxcl10anditaccxcl11concentrationsafternasalallergenchallengeinpatientswithallergicrhinitis